Open Government Portal

Notice of Compliance with Conditions - Qualifying Notice.

Notice of Compliance with Conditions - Qualifying Notice.

Notice of Compliance with Conditions - Qualifying Notice.

The purpose of this Notice of Amendment is to notify the addition of avilamycin to both the Human and Veterinary Prescription Drug List (PDL).

The purpose of this Notice of Amendment is to notify about the addition of casirivimab and imdevimab to the Prescription Drug List (PDL) for human and veterinary use.

The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing for diclofenac on the Prescription Drug List (PDL). Only the Human part of the PDL was revised; the listing for Veterinary use will remain unchanged.

The purpose of this Notice of Amendment is to notify that Health Canada will switch certain uses of Esomeprazole to nonprescription status for human use by modifying the Human Prescription Drug List (PDL). The Veterinary List will remain unchanged.

The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing for omeprazole on the Prescription Drug List (PDL). Only the Human part of the PDL was revised; the listing for Veterinary use will remain unchanged.

The purpose of this Notice of Amendment is to notify that Health Canada will revise the listing for Adrenocortical hormones on the Prescription Drug List (PDL) to exempt certain uses of Fluticasone propionate.

The purpose of this Notice of Amendment is to notify that Health Canada has amended 14 antimicrobial active ingredients or their salts or derivatives from non-prescription to prescription on the Veterinary Prescription Drug List (PDL). These amendments include adding antimicrobial classes, listing certain antimicrobials as derivatives rather than as antibiotic classes, and deleting qualifiers that are no longer necessary.